
## **Zachary Simmons**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1712656/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Amyotrophic lateral sclerosis. Nature Reviews Disease Primers, 2017, 3, 17071.	18.1	885
2	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	3.8	517
3	Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene. Nature Genetics, 1997, 16, 407-409.	9.4	205
4	<scp>COVIDâ€19–associated Guillainâ€Barré</scp> syndrome: The early pandemic experience. Muscle and Nerve, 2020, 62, 485-491.	1.0	196
5	Primary lateral sclerosis: consensus diagnostic criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 373-377.	0.9	118
6	Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. Journal of the Neurological Sciences, 2004, 227, 27-33.	0.3	114
7	Update on diabetic neuropathy. Current Opinion in Neurology, 2002, 15, 595-603.	1.8	99
8	Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle and Nerve, 2012, 46, 9-25.	1.0	96
9	Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 413-418.	0.9	95
10	Management Strategies for Patients With Amyotrophic Lateral Sclerosis From Diagnosis Through Death. Neurologist, 2005, 11, 257-270.	0.4	92
11	Isaacs syndrome: A review. Muscle and Nerve, 2015, 52, 5-12.	1.0	88
12	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186.	4.5	79
13	A randomized trial of mexiletine in ALS. Neurology, 2016, 86, 1474-1481.	1.5	72
14	Pseudobulbar affect: prevalence and management. Therapeutics and Clinical Risk Management, 2013, 9, 483.	0.9	70
15	Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. , 1997, 20, 1569-1575.		68
16	Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. Journal of the Neurological Sciences, 1993, 120, 60-63.	0.3	67
17	Incorporation of telehealth into a multidisciplinary ALS Clinic: feasibility and acceptability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 555-561.	1.1	67
18	Patient-Perceived Outcomes and Quality of Life in ALS. Neurotherapeutics, 2015, 12, 394-402.	2.1	63

#	Article	IF	CITATIONS
19	Hypothyroid myopathy with a strikingly elevated serum creatine kinase level. Muscle and Nerve, 2002, 26, 141-144.	1.0	62
20	Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. , 1997, 20, 1008-1015.		59
21	Localized hypertrophic neuropathy: Magnetic resonance imaging findings and long-term follow-up. , 1999, 22, 28-36.		59
22	A rapid screening battery to identify frontal dysfunction in patients with ALS. Neurology, 2006, 67, 2070-2072.	1.5	55
23	Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism. ELife, 2018, 7, .	2.8	53
24	Religiousness is related to quality of life in patients with ALS. Neurology, 2003, 60, 1527-1529.	1.5	51
25	A Qualitative Study of Multidisciplinary ALS Clinic Use in the United States. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 55-61.	1.1	50
26	Verbal communication impacts quality of life in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 179-183.	1.1	49
27	Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 36-41.	2.3	47
28	Association of Variants in the <i>SPTLC1</i> Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	4.5	46
29	Factors supporting quality of life over time for individuals with amyotrophic lateral sclerosis: the role of positive self-perception and religiosity. Annals of Behavioral Medicine, 2004, 28, 119-125.	1.7	44
30	The SEIQoL-DW for assessing quality of life in ALS: Strengths and limitations. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 456-462.	2.3	44
31	ULTRASOUND IN THE DIAGNOSIS AND MONITORING OF AMYOTROPHIC LATERAL SCLEROSIS: A REVIEW. Muscle and Nerve, 2019, 60, 114-123.	1.0	43
32	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 287-299.	1.1	42
33	Amyotrophic lateral sclerosis care and research in the United States during the <scp>COVID</scp> â€19 pandemic: Challenges and opportunities. Muscle and Nerve, 2020, 62, 182-186.	1.0	42
34	Muscle biopsy in the evaluation of patients with modestly elevated creatine kinase levels. Muscle and Nerve, 2003, 27, 242-244.	1.0	39
35	The Use of Telehealth to Enhance Care in ALS and other Neuromuscular Disorders. Muscle and Nerve, 2020, 61, 682-691.	1.0	39
36	Psychological health in patients with ALS is maintained as physical function declines. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 290-296.	2.3	37

#	Article	IF	CITATIONS
37	Patient-reported problematic symptoms in an ALS treatment trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 198-205.	1.1	37
38	Reproducibility of motor unit number estimation in individual subjects. Muscle and Nerve, 2001, 24, 467-473.	1.0	35
39	Problem solving skills predict quality of life and psychological morbidity in ALS caregivers. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 147-153.	2.3	35
40	The potential of psychological interventions to improve quality of life and mood in muscle disorders. Muscle and Nerve, 2015, 52, 131-136.	1.0	35
41	Psychological morbidity in ALS: The importance of psychological assessment beyond depression alone. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 351-358.	2.3	32
42	The Neuromuscular Manifestations of Amyloidosis. Journal of Clinical Neuromuscular Disease, 2010, 11, 145-157.	0.3	31
43	Pain in amyotrophic lateral sclerosis: Patient and physician perspectives and practices. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 21-29.	1.1	31
44	Evaluation of remote pulmonary function testing in motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 348-355.	1.1	28
45	Understanding the needs of people with ALS: a national survey of patients and caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 355-363.	1.1	27
46	Tocilizumab is safe and tolerable and reduces <scp>C</scp> â€reactive protein concentrations in the plasma and cerebrospinal fluid of <scp>ALS</scp> patients. Muscle and Nerve, 2021, 64, 309-320.	1.0	27
47	H63D HFE genotype accelerates disease progression in animal models of amyotrophic lateral sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2413-2426.	1.8	26
48	Advance care planning for patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 388-396.	1.1	26
49	Telemedicine to innovate amyotrophic lateral sclerosis multidisciplinary care: The time has come. Muscle and Nerve, 2019, 59, 3-5.	1.0	25
50	Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials. Muscle and Nerve, 2020, 62, 321-326.	1.0	24
51	Non-invasive ventilation and gastrostomy may not impact overall quality of life in patients with ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 55-58.	2.3	23
52	Relationship of creatine kinase to body composition, disease state, and longevity in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 473-477.	1.1	23
53	Statins accelerate disease progression and shorten survival in SOD1 <sup>G93A</sup> mice. Muscle and Nerve, 2016, 54, 284-291.	1.0	23
54	Amyotrophic lateral sclerosis–specific quality of life–short form (ALSSQOL‧F): A brief, reliable, and valid version of the ALSSQOLâ€R. Muscle and Nerve, 2018, 58, 646-654.	1.0	21

#	Article	IF	CITATIONS
55	Electrodiagnosis of Brachial Plexopathies and Proximal Upper Extremity Neuropathies. Physical Medicine and Rehabilitation Clinics of North America, 2013, 24, 13-32.	0.7	20
56	Lawful physician-hastened death. Neurology, 2018, 90, 420-422.	1.5	19
57	Multidisciplinary ALS clinics in the USA: A comparison of those who attend and those who do not. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 196-201.	1.1	17
58	Primary Lateral Sclerosis and Early Upper Motor Neuron Disease. Journal of Clinical Neuromuscular Disease, 2016, 17, 99-105.	0.3	17
59	Primary lateral sclerosis (PLS) functional rating scale: PLSâ€specific clinimetric scale. Muscle and Nerve, 2020, 61, 163-172.	1.0	17
60	Rehabilitation of motor neuron disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 110, 483-498.	1.0	15
61	The role of mental health and self-efficacy in the pain experience of patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 206-212.	1.1	15
62	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle and Nerve, 2021, 63, 371-383.	1.0	13
63	Sporadic Inclusion Body Myositis and Hereditary Inclusion Body Myopathy. Journal of Clinical Neuromuscular Disease, 2002, 3, 122-132.	0.3	12
64	An online non-meditative mindfulness intervention for people with ALS and their caregivers: a randomized controlled trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 116-127.	1.1	12
65	Ethical Considerations in Dementia Diagnosis and Care. Neurology, 2021, 97, 80-89.	1.5	12
66	Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 167-172.	1.1	11
67	Neurophysiological features of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 11-17.	1.1	11
68	Variation of calculated ulnar motor conduction velocity across the elbow with body mass index. , 1997, 20, 1607-1608.		10
69	Compliance with recommendations made in a multidisciplinary ALS clinic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 30-37.	1.1	9
70	Can we eliminate placebo in ALS clinical Trials?. Muscle and Nerve, 2009, 39, 861-865.	1.0	8
71	The P300 †face' speller is resistant to cognitive decline in ALS. Brain-Computer Interfaces, 2017, 4, 225-235.	0.9	8
72	Hydration measured by doubly labeled water in ALS and its effects on survival. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 220-231.	1.1	8

#	Article	IF	CITATIONS
73	Inertial sensing of step kinematics in ambulatory patients with ALS and related motor neuron diseases. Journal of Medical Engineering and Technology, 2021, 45, 486-493.	0.8	6
74	Symptom management in amyotrophic lateral sclerosis: We can do better. Muscle and Nerve, 2018, 57, 1-3.	1.0	5
75	Ethical Considerations in Neurogenetic Testing. Seminars in Neurology, 2018, 38, 505-514.	0.5	5
76	VALUESâ€: a national multicenter study of regional and gender differences in frontotemporal disease in amyotrophic lateral sclerosis. Neurodegenerative Disease Management, 2012, 2, 325-336.	1.2	4
77	Ethical issues in the evaluation of adults with suspected genetic neuromuscular disorders. Muscle and Nerve, 2016, 54, 997-1006.	1.0	4
78	Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle and Nerve, 1997, 20, 1008-1015.	1.0	3
79	So many submissions…so little space. Muscle and Nerve, 2017, 55, 299-300.	1.0	2
80	Telemedicine for the Care of Neuromuscular Disorders. Current Treatment Options in Neurology, 2020, 22, 1.	0.7	2
81	Terminology in Neuromuscular Electrodiagnostic Medicine and Ultrasound: Time for an Update. Muscle and Nerve, 2020, 62, 1-1.	1.0	2
82	In defense of the AAN position on lawful physician-hastened death. Neurology, 2020, 94, 641-643.	1.5	2
83	Palliative specialists for patients with <scp>ALS</scp> : Making best use of a limited resource. Muscle and Nerve, 2021, 63, 790-792.	1.0	2
84	Ten years of riluzole use in a tertiary ALS clinic. Muscle and Nerve, 2022, 65, 659-666.	1.0	2
85	Treatment of Diabetic Neuropathy. , 0, , 555-576.		1
86	What's in the Literature?. Journal of Clinical Neuromuscular Disease, 2010, 11, 223-228.	0.3	1
87	Loss and well-being in ALS: A different perspective on the challenge. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 163-164.	1.1	1
88	Muscle & nervejoins the "App World― Muscle and Nerve, 2016, 53, 1-2.	1.0	1
89	Article submission: The scope of muscle & amp; nerve. Muscle and Nerve, 2017, 55, 615-616.	1.0	1
90	Expansion of C9ORF72 in amyotrophic lateral sclerosis correlates with brain-computer interface performance. Scientific Reports, 2017, 7, 8875.	1.6	1

#	Article	IF	CITATIONS
91	Physicianâ€hastened death in <scp>California</scp> for patients with amyotrophic lateral sclerosis: Part of a bigger picture. Muscle and Nerve, 2021, 64, 381-384.	1.0	1
92	What's in the Literature?. Journal of Clinical Neuromuscular Disease, 2012, 13, 162-167.	0.3	0
93	Neuromuscular images: A picture can be worth more than a thousand words. Muscle and Nerve, 2017, 56, 1-1.	1.0	Ο
94	A new editor: Changes in Muscle & amp; Nerve. Muscle and Nerve, 2017, 55, 1-2.	1.0	0
95	Goodbye to neuromuscular images. Muscle and Nerve, 2018, 57, 167-167.	1.0	Ο
96	Guidelines for Authors: A view from the Editor's desk. Muscle and Nerve, 2018, 59, 147-148.	1.0	0
97	Changing with the times. Muscle and Nerve, 2019, 60, 343-344.	1.0	0
98	What's New at <i>Muscle &amp; amp; Nerve</i> ?. Muscle and Nerve, 2020, 62, 152-153.	1.0	0
99	Laryngospasm: A frequently underrecognized symptom in amyotrophic lateral sclerosis. Muscle and Nerve, 2022, , .	1.0	Ο